Nasdaq GlobeNewswire

Gunvor USA Secures USD 875 Million Borrowing Base Facility

Del

Gunvor Group Ltd / Gunvor USA Secures USD 875 Million Borrowing Base Facility . Processed and transmitted by Nasdaq Corporate Solutions. The issuer is solely responsible for the content of this announcement.

HOUSTON, Nov. 07, 2017 (GLOBE NEWSWIRE) -- Gunvor USA LLC, a subsidiary of Gunvor Group, has successfully closed the syndication of its USD 875 million Borrowing Base Credit Facility. The facility will support the company's established operations in the United States, as well as planned expansion into Canada. Gunvor USA LLC has two main offices, located in Houston (TX) and Stamford (CT), which are focused on trading refined products, crude oil and natural gas.

"Our expanded facility enables Gunvor USA to build on our trading activities across the commodities space in North America," said Chris Morran, Treasurer of Gunvor USA. "The oversubscription of the transaction and 75% increase in the facility amount demonstrate the level of confidence our banking partners have with our North American strategy."

The new facility is jointly lead arranged by Rabobank, which will also serve as Administrative Agent and Active Bookrunner, and ABN Amro Capital USA LLC as Joint Bookrunner. ING Capital, LLC, Natixis, New York Branch, and Société Générale join as Joint Lead Arranger in the transaction. The syndicate also includes Credit Agricole Corporate and Investment Bank, Deutsche Bank AG, New York Branch, Mizuho Ltd. and Sumitomo Mitsui Banking Corporation.

"Gunvor USA has grown rapidly since its launch in 2016, and has significantly expanded its bank group as part of the refinancing," said David Garza, President of Gunvor USA and Managing Director for its North American operations. "In the last year, Gunvor USA has hired more than 60 people for its North American operations, and opened trading offices in Houston and Stamford, and now a rep office in Calgary. We've been able to grow at an accelerated pace with the support of our banking partners."

Gunvor USA LLC is a wholly-owned indirect subsidiary of Gunvor Group Ltd., one of the largest independent energy commodity traders in the world.

About Gunvor Group
Gunvor Group is one of the world's largest independent commodities trading houses by turnover, creating logistics solutions that safely and efficiently move physical energy and bulk materials from where they are sourced and stored to where they are demanded most. With strategic investments in industrial infrastructure-refineries, pipelines, storage, terminals, mining and upstream-Gunvor further generates sustainable value across the global supply chain for its customers. More information can be found at GunvorGroup.com or @Gunvor.

  

Contact:
Seth Pietras
Phone Number: +41798706290
Email: seth.pietras@gunvortrade.ch




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Gunvor Group Ltd via Globenewswire

Om Nasdaq GlobeNewswire

Nasdaq GlobeNewswire
Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

+1 212 401 8700http://www.nasdaqomx.com

NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.

Følg saker fra Nasdaq GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Nasdaq GlobeNewswire

Anima Biotech Named U.S. Deal of the Year Winner at Lifestars™ Life Science Awards20.11.2018 16:17Pressemelding

Award recognizes the transformative potential of Anima’s $1B+ collaboration with Lilly BERNARDSVILLE, N.J., Nov. 20, 2018 (GLOBE NEWSWIRE) -- Anima Biotech, the leader in the discovery of drugs that specifically control protein translation, has been named winner of the “U.S. Deal of the Year” award at the 2018 Lifestars AwardsTM. “We are delighted to receive this award, which recognizes the power and potential of our Translation Control Therapeutics platform,” said Yochi Slonim, co-founder and chief executive officer of Anima Biotech. “Our deal with Lilly further validates our approach and our partnering strategy of creating exclusive collaborations around our partners’ chosen targets.” “Lifestars presented a fantastic opportunity to bring together a deserved audience and highlight the advances being made in our industry. It’s a testament to Anima Biotech’s efforts that this year’s judging faculty commended them in this manner,” said Neil Darkes, Co-CEO, LSX Ltd. And Lifestars. The int

Cernostics Secures Additional Patents for Proprietary Barrett’s Esophagus Clinical Diagnostics20.11.2018 15:00Pressemelding

US and EU patents for TissueCypher® cover methods for detecting risk of progression to esophageal cancer in Barrett’s esophagus patients PITTSBURGH, Nov. 20, 2018 (GLOBE NEWSWIRE) -- Cernostics, developer of next-generation cancer diagnostics and prognostics, announced that it has received a U.S. Patent and a European Notice to Grant for the company’s TissueCypher® Barrett’s Esophagus Assay, adding protection to previously awarded foundational, platform patents granted in 2014. Earlier this month, Cernostics received notification from the European Patent Office that claims will be issued for its patent entitled “Systems and Compositions for Diagnosing Barrett’s Esophagus and Methods for Using the Same.” This notice comes on the heels of a recent issuance of a corresponding U.S. patent (U.S. Patent No. 10,018,631). Cernostics’ recent patent claims relate to the company’s clinical test for predicting disease progression in patients with BE and assessment of the likelihood that BE may fur

Gratomic Announces Over-Subscription Non-Brokered Private Placement20.11.2018 14:00Pressemelding

TORONTO, Nov. 20, 2018 (GLOBE NEWSWIRE) -- Gratomic Inc. (“GRAT” or the “Company”) (TSX-V: GRAT) (FRANKFURT:CB81, WKN:A143MR) is pleased to announce that the offering of a non-brokered private placement announced on November 16, 2018 has been over-subscribed and the Company will be offering up to 20,000,000 working capital units (the “WC Unit”) for up to $2,000,000 (the “Offering”). Each WC Unit is priced at $0.10 and consists of one (1) common share and one (1) common share purchase warrant (“WC Warrant”). Each WC Warrant entitles the holder to purchase one (1) common share (a “WC Warrant Share”) at a price of $0.20 per WC Warrant Share until the earlier of: (i) three (3) years following the Closing of the Offering; and (ii) in the event that the closing price of the Common Shares on the TSX Venture Exchange is at least $0.30 for ten (10) consecutive trading days, and the 10th trading day (the “Final Trading Day”) is at least four (4) months from the Closing Date, the date which is th

Ondot Systems Named One of North America’s Fastest Growing Companies in Deloitte’s 2018 Technology Fast 500™20.11.2018 14:00Pressemelding

Ranked Fastest Growing FinTech Company in Silicon Valley with 224 percent revenue growth and over four thousand Financial Institutions now offering its white label service Santa Clara, California, Nov. 20, 2018 (GLOBE NEWSWIRE) -- Ondot Systems, the leading provider of Digital Card Services and Customer Empowerment Solutions, today announced that it was named by Deloitte’s Technology Fast 500TM as the fastest growing Silicon Valley FinTech company, and one of the 500 fastest growing technology, media, telecommunications, life sciences and energy tech companies in North America. A recent report “Accelerating Digital Transformation in Banking” published by Deloitte on results of a survey of 17,100 consumers across 17 countries concluded that leading technology companies have become the gold standard for digital engagement, thus driving a stronger emotional connection for consumers with these brands over their primary banks. If banks want to keep up, they must engineer their digital exper

Patton Delivers IPv6 Services at the Network Edge20.11.2018 13:15Pressemelding

Implementing enhanced IPv6 in SmartNode VoIP CPE, Patton supports simplified network architectures and lowers operation and maintenance costs for service providers and enterprises. SmartNode VoIP… More than Just Talk! GAITHERSBURG, Md., Nov. 20, 2018 (GLOBE NEWSWIRE) -- Patton Electronics—doing business as a bricks-and-mortar manufacturer since 1984—has enhanced IPv6 in its SmartNode CPE, the company announced today. Global expansion of the Internet, proliferation of IP endpoint devices, and the burgeoning Internet of Things (IoT) means we will soon run out of IPv4 addresses. The IPv6 standard expands available IP addresses octillion times, or at least 17 billion . Everyone has known that for a long time and the hype has been going on for years. Service providers made plans, and some partially implemented IPv6 in their networks. Carriers like Telefonica and T-MOBILE—and enterprises such as Microsoft—have started the changeover. Many large enterprises also planned on it, but have spotty

SoftServe Achieves ISO 13485 Standard for Medical Device Quality Management Systems20.11.2018 13:00Pressemelding

International standard ensures customer and regulatory requirements are consistently met for the lifecycle of medical device products AUSTIN, Texas, Nov. 20, 2018 (GLOBE NEWSWIRE) -- SoftServe, a leading digital authority and consulting company, announces it has achieved the ISO 13485:2016 standard – an internationally recognized standard that defines quality management system requirements for medical device manufacturers as set by the International Organization for Standardization (ISO). SoftServe implemented and established a quality management system compliant with the requirements of ISO 13485:2016. This activity was verified by third-party audits by Loyd’s Register, an accredited certification company. One critical advantage of the certification is it cultivates a preventative approach to assure software medical device quality versus a reactive approach of inspection and rejection during production. “With software as a medical device and software in a medical device continuing to

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom